Hereditary transthyretin amyloidosis (ATTRv) is a rare genetic disorder caused by the deposition of misfolded transthyretin (TTR) proteins, leading to widespread organ dysfunction.¹ Advances in understanding the pathogenesis of ATTRv have paved the way for novel therapeutic strategies beyond traditional liver transplantation.¹ Among these, ribonucleic acid interference (RNAi) therapy has emerged as a pivotal development.^1,2 At the 38^th Annual Scientific Meeting of the Hong Kong Neurological Society, Dr. Matt Silsby from Westmead Hospital in Australia, highlighted the expanding impact of RNAi therapies such as vutrisiran in addressing the root cause of ATTRv and reshaping the disease trajectory and expanding the horizons of clinical management.

ATTRv is a rare but debilitating genetic condition caused by pathogenic variants in the transthyretin (TTR) gene.¹ These variants destabilize the TTR tetramer and trigger an amyloidogenic cascade in which dissociated monomers misfold, aggregate, and deposit as amyloid fibrils across multiple organs.¹

ATTRv presents with striking heterogeneity.¹ Although approximately 10,000 individuals worldwide are affected, their clinical manifestations vary widely depending on genotype and disease stage.^1,3 Patients may display neuropathic, cardiac, or mixed phenotypes.^1,3 Early features include progressive sensory and motor neuropathy, gait disturbance, and autonomic dysfunction, while cardiac involvement can manifest as conduction abnormalities or restrictive cardiomyopathy.¹ Notably, carpal tunnel syndrome may precede systemic disease by years, often leading to diagnostic delays.¹

Given this complexity, timely and accurate diagnosis is essential.¹ A comprehensive evaluation typically integrates clinical assessment, electrophysiological studies, imaging, histopathology, and genetic confirmation.¹ Nerve conduction studies help characterize axonal neuropathy, while cardiac scintigraphy offers high sensitivity for detecting TTR amyloid deposition when monoclonal gammopathy is excluded.^1,4 Tissue biopsy with laser microdissection mass spectrometry remains the gold standard for amyloid typing.^1,4 Genetic testing not only confirms the hereditary nature of ATTRv but also enables family screening and early detection.^1,4 These diagnostic steps are crucial, as early identification directly affects therapeutic outcomes.¹

Historically, options were limited, with liver transplantation serving as the primary disease-modifying intervention.¹ However, as the understanding of ATTRv deepened, treatment strategies have evolved from symptom control alone to a more mechanism-based approach.¹ Management today is inherently multidisciplinary, involving neurologists, cardiologists, geneticists, hematologists, and allied health professionals.⁵ While symptom management—addressing gastrointestinal dysfunction, orthostatic hypotension, neuropathic pain, and mobility challenges—remains important, disease-modifying therapies have shifted expectations.¹ TTR stabilizers such as tafamidis and RNAi therapies, including vutrisiran and patisiran, represent a fundamental shift toward targeting the molecular origin of disease.¹

As a next-generation subcutaneous RNAi therapy, vutrisiran suppresses production of both wild-type and variant TTR, achieving rapid, deep, and sustained reductions in serum TTR levels.² The phase 3 HELIOS-A study provided strong evidence for its clinical impact.² In the trial, vutrisiran did more than slow neurologic decline—it produced measurable improvement.² By month 18, patients receiving vutrisiran demonstrated a 28.55-point benefit in the modified Neuropathy Impairment Score +7 (mNIS+7) vs. placebo (p=6.5 × 10⁻²⁰).² Benefits emerged as early as month 9 and continued to accrue through month 18.² Patients with milder baseline disease experienced even greater preservation of neurologic function, reinforcing the critical value of early initiation.⁶

As TTR serves as the primary carrier of vitamin A, supplementation during therapy remains essential given reduced circulating TTR levels.² Beyond this need for supplementation, vutrisiran was generally well-tolerated and demonstrated an acceptable safety profile.² Most adverse events were mild or moderate and aligned with the clinical manifestations expected in ATTRv.² No treatment-related deaths occurred, and the discontinuation rate was low (2.5%), with none attributed to vutrisiran.²

These insights set the stage for one of the most important advances in ATTRv management: improved treatment adherence driven by convenience.² Dr. Silsby emphasized that vutrisiran’s quarterly subcutaneous administration significantly reduces treatment burden, enabling consistent disease control while supporting long-term compliance. This positions vutrisiran as a cornerstone therapy within an expanding landscape of TTR-targeted strategies designed to intervene earlier and more effectively.²

As the management of ATTRv advances, early recognition remains paramount for achieving optimal patient outcomes.¹ Clinicians must be vigilant in identifying key red flags and maintain a low threshold for genetic testing to minimize diagnostic delays.¹ With heightened awareness and improved access to targeted therapies, ATTRv can be transformed from a condition associated with profound morbidity into one offering measurable stability and renewed hope for patients.¹